Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
Titel:
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
Auteur:
Motzer, Robert J Porta, Camillo Vogelzang, Nicholas J Sternberg, Cora N Szczylik, Cezary Zolnierek, Jakub Kollmannsberger, Christian Rha, Sun Young Bjarnason, Georg A Melichar, Bohuslav De Giorgi, Ugo Grünwald, Viktor Davis, Ian D Lee, Jae-Lyun Esteban, Emilio Urbanowitz, Gladys Cai, Can Squires, Matthew Marker, Mahtab Shi, Michael M Escudier, Bernard